Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference

Rhea-AI Summary

Zosano Pharma Corporation (NASDAQ: ZSAN) announced that its CEO, Steven Lo, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 1:30 PM ET. A live webcast will be accessible on the company's website, with an archive available for 30 days post-event. The company focuses on developing a transdermal microneedle system for rapid drug delivery, particularly its lead candidate Qtrypta™ (M207), aimed at migraine treatment, leveraging established safety and efficacy.

FREMONT, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright 22^nd Annual Global Investment Conference on Monday, September 14, 2020 at 1:30 pm ET.

A live webcast of the event will be available on the company’s website at http://ir.zosanopharma.com/events-presentations. The archived webcast will remain available for 30 days following the date of the presentation.

About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company’s transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano’s lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan delivered via its transdermal microneedle system technology, as an acute treatment for migraine. The company anticipates that many of its current and future development programs may enable the company to utilize a regulatory pathway that has the potential to streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

Zosano Contact:
Christine Matthews
Chief Financial Officer
510-745-1200

PR Contacts:
Sylvia Wheeler or Alexandra Santos
swheeler@wheelhouselsa.com or asantos@wheelhouselsa.com

FAQ

When will Zosano Pharma present at the H.C. Wainwright Conference?

Zosano Pharma will present on September 14, 2020, at 1:30 PM ET.

How can I watch the Zosano Pharma presentation?

The presentation will be available via a live webcast on the company's website.

What is Qtrypta™ (M207) developed by Zosano Pharma?

Qtrypta™ (M207) is Zosano Pharma's lead product candidate for acute migraine treatment using a transdermal microneedle system.

How long will the webcast of the Zosano presentation be available?

The archived webcast will be available for 30 days after the presentation.

What type of technology does Zosano Pharma use for drug delivery?

Zosano Pharma uses a transdermal microneedle system designed for rapid systemic drug administration.